The review said a certain class of drugs had little clinical benefit, but many Alzheimer’s experts criticized the analysis, saying it unfairly lumped failed drugs with two recently approved treatments.
The AMA’s evaluation will be done in collaboration with the Vaccine Integrity Project at the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota and will focus on COVID-19, flu and RSV vaccines.